Ersodetug upLIFT Phase 3 results infographic for tumor hyperinsulinism

Rezolute said on November 13, 2026 that ersodetug cleared the bar in its Phase 3 upLIFT study in tumor hyperinsulinism: 13 of 16 patients with insulin-secreting tumors met the response goal of at least halving their intravenous glucose needs, and 12 came off IV glucose entirely. Full statistical results are due by mid-December, with biologics license applications planned for 2027. For a company whose earlier congenital hyperinsulinism study disappointed, this is the first clean pivotal win.

Key takeaways on ersodetug

  • upLIFT enrolled 16 people (12 with insulinoma, 4 with non-islet cell tumors) whose low blood sugar needed continuous IV glucose.
  • Success required at least 9 responders; 13 have already met the 50% glucose infusion reduction target.
  • 12 participants stopped IV glucose completely during the 8-week pivotal period.
  • No drug-related safety findings have been reported so far.
  • Rezolute plans one or two BLAs in 2027 covering tumor and congenital hyperinsulinism, with FDA talks in Q1 2027.

The patients this trial was built for

Tumor hyperinsulinism occurs when a tumor floods the body with insulin. Most often it is an insulinoma, a usually small pancreatic neuroendocrine tumor; less often it is a non-islet cell tumor that releases insulin-like signals. The result is repeated, sometimes dangerous hypoglycemia: confusion, seizures and loss of consciousness. Surgery cures many insulinomas, but patients with inoperable or spread disease can end up tethered to a glucose drip in hospital. Those were the people upLIFT recruited, which is why getting off IV glucose is such a meaningful endpoint.

How ersodetug works differently

Most existing drugs for hyperinsulinism try to stop insulin from being released. Ersodetug, a fully human monoclonal antibody, works downstream: it binds the insulin receptor at an allosteric site and dampens the receptor’s response to excess insulin. Because it does not depend on what is driving insulin secretion, the same mechanism could, in principle, apply to tumor-driven and congenital forms of the disease. Patients in upLIFT received 9 mg/kg once a week for eight weeks on top of standard care, then could move into an extension with less frequent dosing.

upLIFT results at a glance

MeasureResultShare of 16 (our calculation)
Responders needed for success9 or more56%
Responders so far (50%+ GIR cut)1381%
Fully off IV glucose1275%
Still in pivotal period3 (2 not yet responders)19%
Early exit (counted as non-responder)1, hospice for cancer progression6%
Source: Rezolute, data evaluated November 5, 2026. GIR = glucose infusion rate.

The pre-set success rule was that the lower bound of the 95% confidence interval for the response rate must exceed 30%, which mathematically requires nine responders. With 13 already in hand, the outcome of the primary endpoint is no longer in doubt even if the remaining patients do not respond. CEO Nevan Charles Elam said the findings “substantially mirror” what Rezolute had seen in its expanded access program.

Reading the result carefully

This is a single-arm, open-label study of 16 people, which is common in ultra-rare diseases but limits what it can prove. There is no placebo group, so the size of the benefit is judged against each patient’s own baseline. Formal statistics have not been published, and long-term durability and safety will come from the extension. One participant died of cancer progression after leaving for hospice care; Rezolute does not attribute it to the drug.

Context also matters. Rezolute’s earlier Phase 3 sunRIZE study in congenital hyperinsulinism, the inherited form seen in infants and children, did not meet its primary endpoint in late 2025. Even so, the company says the FDA recommended a BLA for congenital disease after a pre-BLA meeting, though it gives no assurance of approval.

Market context

According to Acumen Research and Consulting, the global congenital hyperinsulinism treatment market was valued at USD 185.6 million in 2022 and is projected to reach USD 327.8 million by 2032, a 5.9% CAGR, with Asia-Pacific the fastest-growing region. That report covers the congenital form only; tumor hyperinsulinism would add a separate, smaller patient pool if ersodetug is approved for both.

Why it matters for patients in India

Ersodetug is not approved anywhere, and Rezolute has not announced trials or filings in India. Any access here would likely follow US approval and a later CDSCO pathway, so for now Indian patients with inoperable insulinoma remain on surgery, diet and existing medicines. Clinicians following rare endocrine tumors may want to track the December data and 2027 filings.

More rare-disease trial coverage: PepGen’s myotonic dystrophy data and CAR-T for lupus. Browse all clinical trials news.

FAQ

What is ersodetug?

An investigational antibody from Rezolute that binds the insulin receptor to blunt the effect of excess insulin, being developed for tumor and congenital hyperinsulinism.

Did ersodetug meet its Phase 3 goal?

Based on preliminary data, yes: 13 of 16 patients responded, above the 9 required. Full statistical analysis is expected by mid-December 2026.

When could ersodetug be approved?

Rezolute plans to file in 2027. A US decision would typically follow 10 to 12 months after an application is accepted.

What is an insulinoma?

A usually small pancreatic tumor that overproduces insulin and causes low blood sugar. Surgery is the standard cure when the tumor can be removed.

Source: Rezolute press release via GlobeNewswire, November 13, 2026. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated November 13, 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

One thought on “Ersodetug Phase 3 upLIFT: 12 of 16 Tumor Hyperinsulinism Patients Come Off IV Glucose”

Leave a Reply

Your email address will not be published. Required fields are marked *